Fostering innovation with partnerships and collaborations
Creating new and better medicines for patients. This commitment is driven by a strong belief in the power of collaboration.
Search
Innovation through Collaboration
Pharmaceutical manufacturers and healthcare professionals regularly interact to learn from each other and improve patient care.
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Innovation in Oncology and Cancer Immunology Research
We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.
Open Innovation Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Gastrointestinal Cancers
Gastrointestinal Cancers
Cancer
At Boehringer Ingelheim we are dedicated to working on improving treatments for cancer patients everywhere with a focus on lung and gastrointestinal cancers.
Animal Health Partnering
Animal Health Partnering
Human Health Partnering
Human Health Partnering
Animal Health Innovation
Animal Health Innovation
Partnering
We are convinced that diversity and exchange in science give birth to innovations. For this reason, partnerships are an important component of our innovation strategy.
Marketplace for Molecules
Boehringer Ingelheim's openMe platform enables open access research .
Swine
Swine
Oncology Translational Science
Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts
Research Institute of Molecular Pathology IMP
Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.
Research Beyond Borders
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Access to Care platform
Discover how Boehringer Ingelheim is addressing health equity and healthcare access in Central and Eastern Europe through the "Access to Care" platform. Learn about the Legal Toolkit designed for patient advocates and the impact of our initiatives in the
Research at the Regional Center Vienna
The Regional Center Vienna counts for 33 countries and has been a central pillar in Boehringer Ingelheim’s global research network.
Embracing diversity in clinical trials: A global mandate
Have you ever wondered why medicines work differently for different people? Each patient is unique. By embracing diversity in clinical trials, we enable more equitable and inclusive healthcare.
Biotherapeutics Discovery
Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
More Potential: Overview
Society continues to face challenges ranging from health to education, work prospects, living conditions, inequalities and poverty, often impacting vulnerable communities the most.
Women in STEM: Passion for science to achieve more sustainable healthcare solutions
Women in STEM: Passion for science to achieve more sustainable healthcare solutions
More Health: Overview
As a company that operates at the intersection of human and veterinary medicine, we have unique opportunities to advocate for disadvantaged populations.
Our FOCUS
Our FOCUS
Immune cell directed therapies
Boehringer Ingelheim is committed to transforming cancer care, investigating therapies that target cancer cells and boost the immune system for the benefit of patients.